ArticleCureus2025
A Comparative Study of 0.5% and 0.75% Ropivacaine for Supraclavicular Brachial Plexus Block in Upper Limb Surgery.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background For surgery of the upper extremity, one method is the supraclavicular block, as it is a reliable anesthetic, safe, and has a rapid onset. Although for epidural anesthesia, ropivacaine has been studied extensively, few reports exist on its use in supraclavicular brachial plexus block in two different concentrations. The present study was done to evaluate the efficacy of 0.5% ropivacaine for supraclavicular brachial plexus block and to compare it with 0.75% ropivacaine for upper limb surgeries in terms of characteristics of supraclavicular blockade. Methods A prospective, blinded randomized study was conducted, enrolling 60 patients of either sex, American Society of Anesthesiologists (ASA) I and II, who were allocated into two groups in which supraclavicular brachial plexus block was performed using ropivacaine in concentrations of 0.5% and 0.75%, respectively. The onset and duration of sensory and motor blocks were recorded. Results The onset of sensory and motor blockade was faster in patients receiving ropivacaine 0.5% than in those receiving ropivacaine 0.75%. However, the sensory and motor blockade duration was longer in patients who received ropivacaine 0.75%, in comparison to patients who received ropivacaine 0.5%. No statistically significant difference was found in the quality of blocks in both groups. Conclusion Ropivacaine 0.75% provides a longer duration of sensory and motor blockade compared to 0.5% when used for supraclavicular brachial plexus block, making it more suitable for prolonged upper limb surgeries and in cases where prolonged pain relief is prioritized. However, 0.5% may be preferable in cases where early motor recovery is desired. Both concentrations were well-tolerated without any significant complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.